StockData

Dianthus Therapeutics vs Spyre Therapeutics

DNTH and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DNTH and SYRE compare

Spyre Therapeutics is the larger company, worth 1.7 times as much as Dianthus Therapeutics ($8.8B against $5.0B).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDNTHSYRE
Size and price
Market cap$5.0B$8.8B
Share price$89.55$99.37
Change, 1 year152%339%
Change, 5 years−7.6%−38.4%
Beta (5Y)0.041.91
Employees92102
StockData Score
Total score77
Valuation score00
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/B4.0× (better)8.0×
Profitability
Return on equity−22.6% (better)−23.0%
Return on invested capital−22.2%–
Financial health
Debt / equity0.000.00
Current ratio30.02 (better)18.53
Altman Z-score85.95 (better)72.25
Piotroski F-score24 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield−0.01%–
Shareholder yield−0.01%0.00% (better)
Ownership
Held by institutions118%109%
Held by insiders9.1%20.3%
Insider net buying, 12 months−$75.1M (better)−$442M
Short interest, % of float18.2%16.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.